EFFICACY EVALUATION OF THE TRANSITION TO FIXED COMBINATION DRUG PRESTANCE IN PATIENTS WITH INSUFFICIENT CONTROL OF BLOOD PRESSURE BY OTHER ANTIHYPERTENSIVE MEDICATIONS OR COMBINATIONS: REGIONAL PROGRAM OBJECTIVE
https://doi.org/10.15829/1728-8800-2018-2-10-16
Abstract
Aim. To evaluate efficacy of the fixed combination of perindopril arginine and amlodipine (original drug PRESTANCE, JSC “Servier”, France) in achievement of blood pressure (BP) control in patients noncontrolled with other antihypertensive medications.
Material and methods. In the study, in real world setting, 250 arterial hypertension (AH) outpatients were included. The levels of systolic (SBP) and diastolic (DBP) blood pressure were assessed and “vascular age”, at baseline, in 1 and 3 months (visit 2) of treatment with PRESTANCE.
Results. In transition of patients to PRESTANCE there was decrease of SBP from 166,6±8,9 to 142,1±6,1 mmHg in 1 month (р<0,001) and to 131,1±6,1 mmHg in 3 months. (р<0,001), that is by 36 mmHg. BP decrease with the studied drug was similar in men and women, in patients older and younger 60. Target BP was reached in 79,6% of patients. The parameter “vascular age” after transition to PRESTANCE decreased in 3 months from 67,3±10,5 y. o. to 59,2±8,86 y. o., that is by 8,1 years.
Conclusion. Transition from mono or combination therapy to fixed combination of perindopril arginine/amlodipine releases rapid and potent antihypertensive efficacy in patients not reached the target BP at any previous therapy, including combination of perindopril with amlodipine.
About the Authors
A. Ya. Kravchenko
N.N. Burdenko Voronezhskiy State Medical University of the Ministry of Health
Russian Federation
Russian Federation
Z. Z. Alimkhanova
N.N. Burdenko Voronezhskiy State Medical University of the Ministry of Health
Russian Federation
Russian Federation
References
1. Chazova IE, Oshchepkova EV, Zhernakova YuV. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Kardiologicheskiy vestnik 2015; 1: 530. (In Russ.)
2. Chazova IE, Oshchepkova EV. Results of the implementation of the Federal Target Program for the Prevention and Treatment of Hypertension in Russia in 20022012. Vestnik RAMN 2013; 2: 411. (In Russ.)
3. Leonova MV, Shteynberg LL, Belousov YuB. and a group of researchers. Pharmacoepidemiology of arterial hypertension in Russia: analysis of adherence of doctors (according to the results of the study “PIFAGOR IV”). Systemic hypertension 2015; 12 (1): 1925. (In Russ.)
4. Shalnova SA. Epidemiology of arterial hypertension in Russia: a portrait of a patient. Arterial hypertension 2008; 2 (2): 814. (In Russ.) Шальнова С. А. Эпидемиология артериальной гипертензии в России: портрет больного. Артериальная гипертензия 2008; 2 (2): 814.
5. Chazova IE, Karpov YuA, Ostroumova OD and the members of the RMSAH Experts Council. Optimization of antihypertensive therapy from the position of correction of increased variability of blood pressure — an additional reduction in the risk of cardiovascular complications. Atmosphere. Cardiology news 2013; 1: 2932. (In Russ.)
6. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Managed Care 1998; 4 (11): 15638.
7. Karpov YuA, Sorokin EV. The effect of combined antihypertensive therapy on the risk of cardiovascular complications and vascular age: results of a multicentre openlabel study ADVANT’AGE. Atmosphere. Cardiology news 2015; 3: 19. (In Russ.)
8. Shestakova MV, Aleksandrov AA, Galitsina NA. The ADVANCE Study: the effect of Noliprel — a fixed combination of an ACE inhibitor (Perindopril) and a diuretic (Indapamide) — on the development of cardiovascular complications in patients with type 2 diabetes mellitus (on materials of the ЕSС congress, ADVANCE Collaborative Group, VIENNA 2007). Diabetes mellitus 2008; 1: 814. (In Russ.)
9. Karpov YuA. European recommendations for the diagnosis and treatment of hypertension 2013: a new target level of blood pressure and how to achieve it in real practice. Atmosphere. Cardiology news 2013; 3: 28. (In Russ.)
10. Karpov YuA, on behalf of doctors participating in the PRORYV program. Achieving target blood pressure in patients with uncontrolled arterial hypertension when transferred from monoor combination therapy to a fixed combination of an angiotensinconverting enzyme inhibitor and a calcium antagonist. Arterial hypertension 2012; 6: 48490. (In Russ.)
11. Karpov YuA, Gorbunov VM, Deev AD, on behalf of doctors participating in the PRORYV 2 program). PRORYV 2 Study: the effect of a fixed combination of perindopril/ amlodipine on blood pressure measured in the doctor’s office, with daily monitoring and selfmonitoring, in patients with uncontrolled arterial hypertension. Atmosphere. Cardiology news 2014; 1: 28. (In Russ.)
12. Chazova IE, Ageev FT, Smirnova MD, et al. Evaluation of the efficacy and safety of a fixed combination of amlodipine and perindopril (Prestans) in hypertensive patients during the summer heat. Systemic hypertension 2014; 2: 1722. (In Russ.)
13. Karpov YuA, Sorokin EV. Assessment of the risk of complications in arterial hypertension and vascular age: new tools for improving the quality of treatment and improving the understanding between the doctor and the patient. Atmosphere. Cardiology news 2015; 2: 1824. (In Russ.)
14. Cuende JI, Cuende N, CalaverasLagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart 2010; 31: 23518. DOI: 10.1093/eurheartj/ehq205.
Review
For citations:
Kravchenko A.Ya., Alimkhanova Z.Z. EFFICACY EVALUATION OF THE TRANSITION TO FIXED COMBINATION DRUG PRESTANCE IN PATIENTS WITH INSUFFICIENT CONTROL OF BLOOD PRESSURE BY OTHER ANTIHYPERTENSIVE MEDICATIONS OR COMBINATIONS: REGIONAL PROGRAM OBJECTIVE. Cardiovascular Therapy and Prevention. 2018;17(2):10-16. (In Russ.) https://doi.org/10.15829/1728-8800-2018-2-10-16
Views:
2066
Email this article 
